BIFIDOBACTERIUM LONGUM FOR TREATING OBESITY AND WEIGHT MANAGEMENT

John Cryan; Ted Dinan; Catherine Stanton; Harriet Schellekens; Cristina Torres; Bernard Roy

BIFIDOBACTERIUM LONGUM FOR TREATING OBESITY AND WEIGHT MANAGEMENT

John Cryan (Inventor)
, Ted Dinan (Inventor)
, Catherine Stanton (Inventor)
, Harriet Schellekens (Inventor)
, Cristina Torres (Inventor)
, Bernard Roy (Inventor)

Teagasc - Irish Agriculture and Food Development Authority

Research output: Patent

Abstract

A strain of Bifidobacterium longum APC 1472 is described. The strain has weight lowering effects in-vivo, achieved through inducing satiety via decreased internalisation of the Ghrelin receptor, and therefore, decreased constitutive activity. Moreover, the strain also showed a trend towards decreased ghrelin receptor hypothalamic expression in HFD-fed mice when compared with vehicle control group. The strain also improves glucose tolerance and decreased insulin plasma levels in mice, indicating the strain in the prevention and/or treatment of Type II diabetes, especially in obese individuals.

Original language	English
Patent number	WO2019038449
IPC	C12R 1/ 01 A N
Priority date	25/08/17
Publication status	Published - 28 Feb 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@misc{39939a273e6742e0a01f770d1b0689ea,

title = "BIFIDOBACTERIUM LONGUM FOR TREATING OBESITY AND WEIGHT MANAGEMENT",

abstract = "A strain of Bifidobacterium longum APC 1472 is described. The strain has weight lowering effects in-vivo, achieved through inducing satiety via decreased internalisation of the Ghrelin receptor, and therefore, decreased constitutive activity. Moreover, the strain also showed a trend towards decreased ghrelin receptor hypothalamic expression in HFD-fed mice when compared with vehicle control group. The strain also improves glucose tolerance and decreased insulin plasma levels in mice, indicating the strain in the prevention and/or treatment of Type II diabetes, especially in obese individuals.",

author = "John Cryan and Ted Dinan and Catherine Stanton and Harriet Schellekens and Cristina Torres and Bernard Roy",

year = "2019",

month = feb,

day = "28",

language = "English",

type = "Patent",

note = "WO2019038449; C12R 1/ 01 A N",

}

TY - PAT

T1 - BIFIDOBACTERIUM LONGUM FOR TREATING OBESITY AND WEIGHT MANAGEMENT

AU - Cryan, John

AU - Dinan, Ted

AU - Stanton, Catherine

AU - Schellekens, Harriet

AU - Torres, Cristina

AU - Roy, Bernard

PY - 2019/2/28

Y1 - 2019/2/28

N2 - A strain of Bifidobacterium longum APC 1472 is described. The strain has weight lowering effects in-vivo, achieved through inducing satiety via decreased internalisation of the Ghrelin receptor, and therefore, decreased constitutive activity. Moreover, the strain also showed a trend towards decreased ghrelin receptor hypothalamic expression in HFD-fed mice when compared with vehicle control group. The strain also improves glucose tolerance and decreased insulin plasma levels in mice, indicating the strain in the prevention and/or treatment of Type II diabetes, especially in obese individuals.

AB - A strain of Bifidobacterium longum APC 1472 is described. The strain has weight lowering effects in-vivo, achieved through inducing satiety via decreased internalisation of the Ghrelin receptor, and therefore, decreased constitutive activity. Moreover, the strain also showed a trend towards decreased ghrelin receptor hypothalamic expression in HFD-fed mice when compared with vehicle control group. The strain also improves glucose tolerance and decreased insulin plasma levels in mice, indicating the strain in the prevention and/or treatment of Type II diabetes, especially in obese individuals.

M3 - Patent

M1 - WO2019038449

ER -

BIFIDOBACTERIUM LONGUM FOR TREATING OBESITY AND WEIGHT MANAGEMENT

Abstract

UN SDGs

Fingerprint

Cite this